Operating Segments

6 Months Ended

12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended  June 30,
	2014			2013
Contract/Grant Revenue
Vaccines/BioDefense	$	1,321,385		$	588,496
BioTherapeutics		96,863			43,782
Total	$	1,418,248		$	632,278
Income (Loss) from Operations
Vaccines/BioDefense	$	264,810		$	(1,532,472	)
BioTherapeutics		(650,477	)		(530,640	)
Corporate		(1,310,164	)		(692,772	)
Total	$	(1,695,831	)	$	(2,755,884	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,809		$	27,968
BioTherapeutics		49,072			28,675
Corporate		1,526			424
Total	$	60,407		$	57,067
Other Income /(Expense), Net
Corporate	$	747,314		$	(649,273	)
Stock-Based Compensation
Vaccines/BioDefense	$	10,450		$	11,128
BioTherapeutics		33,135			25,905
Corporate		77,672			47,755
Total	$	121,257		$	84,788

	Six Months Ended  June 30,
	2014			2013
Revenues, Principally from Grants
Vaccines/BioDefense	$	2,198,430		$	1,418,345
BioTherapeutics		130,415			114,287
Total	$	2,328,845		$	1,532,632
Income (Loss) from Operations
Vaccines/BioDefense	$	404,214		$	(1,563,467	)
BioTherapeutics		(1,686,068	)		(988,266	)
Corporate		(2,003,886	)		(1,292,048	)
Total	$	(3,285,740	)	$	(3,843,781	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	19,744		$	55,635
BioTherapeutics		99,011			57,070
Corporate		3,739			861
Total	$	122,494		$	113,566
Other Income /(Expense), Net
Corporate	$	(994,485	)	$	(648,790	)
Stock-Based Compensation
Vaccines/BioDefense	$	20,900		$	22,249
BioTherapeutics		109,256			46,941
Corporate		167,763			95,090
Total	$	297,919		$	164,280

	As of  June 30,  2014		As of  December 31,  2013
Identifiable Assets
Vaccines/BioDefense	$	702,507	$	1,870,414
BioTherapeutics		313,022		386,721
Corporate		5,130,406		6,008,320
Total	$	6,145,935	$	8,265,455

Note 10. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Year Ended December 31,
	2013			2012
Revenues
Vaccines/BioDefense	$	3,003,822		$	2,919,677
BioTherapeutics		220,330			224,943
Total	$	3,224,152		$	3,144,620
Loss from Operations
Vaccines/BioDefense	$	(1,666,130	)	$	(33,636	)
BioTherapeutics		(3,069,998	)		(2,203,721	)
Corporate		(2,420,414	)		(2,453,311	)
Total	$	(7,156,542	)	$	(4,690,668	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	37,981		$	38,589
BioTherapeutics		190,033			190,003
Corporate		2,057			2,038
Total	$	230,071		$	230,630
Interest Income
Corporate	$	1,960		$	6,202
Stock-Based Compensation
Vaccines/BioDefense	$	80,432		$	44,484
BioTherapeutics		250,431			84,020
Corporate		472,197			333,666
Total	$	803,060		$	462,170

	As of December 31,
	2013		2012
Identifiable Assets
Vaccines/BioDefense	$	1,870,414	$	628,494
BioTherapeutics		386,721		566,111
Corporate		6,008,320		3,510,499
Total	$	8,265,455	$	4,705,104